The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP).
Introduction
Recent progress has been observed in developing therapies to treat HIV infection, particularly the highly active antiretroviral therapy (HAART). HAART represents a combination of antiretroviral agents, reverse transcriptase inhibitors, and protease. [1] [2] [3] [4] [5] [6] [7] [8] This therapeutic strategy results in a significant reduction of morbidity, prevalence of some oral lesions, and mortality associated with HIV infection. HAART, therefore, can substantially extend an HIV patient's life. [4] [5] [6] [7] [8] [9] [10] However, one of the major problems with HAART are its adverse systemic and orofacial effects (Table 1) .
Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which has occasionally been associated with systemic and orofacial adverse effects. 1, 3, 7, [12] [13] [14] [15] The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of NVP in a 29-year-old HIV-infected black man.
Case Report
In July 2002 a 29-year-old black man was referred to the Dental Service of the Orestes Diniz's Treatment Center for Parasitic and Infectious Diseases in Belo Horizonte, MG, Brazil. The patient presented with whitish plaque on his oral mucosa, which had evolved over one month. His medical history revealed an HIV infection since 1996, the presence of gonorrhea, hepatitis B, bronchitis, and bilateral maxillary sinusitis. In March 1998 his physician chose to begin antiretroviral therapy using zidovudine as the patient presented with a T CD4 lymphocyte count of 158 cells/mm 3 . In March 1999 the patient was taking zidovudine, lamivudine, and indinavi when he presented with renal colic and fever. In July 1999 the indinavir was replaced with nelfinavir but the patient developed a cutaneous rash. Subsequently, the nelfinavir was replaced with efavirenz but the patient presented with nausea and temporary memory loss. A month before the patient presented at the Dental Service clinic in and dentists alike must understand how to identify and prevent these adverse effects in order to further improve HIV patient treatments. 4, 5, 7, 10, 11 plaque began to appear when the patient began treatment with NVP. To our knowledge, this is the first case in the literature reporting on this type of oral effect stemming from NVP usage. Other orofacial adverse effects of HAART-related medications are displayed in Table 2 . A biopsy was not performed as the patient's medical history was highly suggestive of an adverse effect caused by NVP. In addition, the discontinuation of his medication led to the complete clinical resolution of signs and symptoms. The taste disturbance and oral burning sensation may have also been caused by NVP as the patient's other antiretroviral medications (zidovudine and lamivudine), taken by the patient at the moment of June of 2002 when the efavirenz was exchanged for NVP so his medication included NVP, zidovudine, and lamivudine at that time.
Keywords
The patient's CD4 lymphocyte count was 532 cells/mm 3 ; the CD8 lymphocyte count was 582 cells/mm 3 ; the CD4/CD8 lymphocyte count was 0.91; and viral load was 255 copies/mL. The oral examination revealed a non-removable whitish plaque on the lips and bilateral buccal mucosa ( Figures 1A and 1B) and the dorsum of the tongue without papillae.
The patient complained of a taste disturbance, xerostomia, and a burning sensation in the mucosa. He reported no use of secondary medication, mouthwashes, or a change of toothpastes. The medical history suggested a provisory clinical diagnosis of an adverse oral effect due to the use of NVP. Consequently, antiretroviral therapy was suspended by his physician.
The physician chose to prescribe no antiretrovirals or secondary medication because of the patient's history of several adverse effects to different HAART medications; the patient was well without any opportunistic infection and his CD4 lymphocyte count was above 200 cells/mm 3 . After one week, the patient returned with a significant improvement in the symptoms of burning, taste, xerostomia, and a partial disappearance of the whitish plaques on buccal mucosa and lips. Seven months later a total remission of the oral effect of the NVP was achieved ( Figure 1C  and 1D ).
Without antiretroviral therapy during three years and five months of follow-up treatment the patient showed no negative oral effects. He also presented with no opportunistic infection or any other complaints. The patient's CD4 lymphocyte count was 343 cells/mm 3 , the CD8 was 607 cells/ mm 3 , the CD4/CD8 was 0.57, and the viral load was 2.489 copies/mL. As a result, the clinical diagnosis was finalized as an oral adverse effect due to the use of NVP. The patient has been receiving follow-up treatment by dentists and physicians since that time.
Discussion
This article supports a case report of an adverse oral effect due to the use of NVP. The oral whitish cholesterol levels. 1, [16] [17] [18] However, the most common adverse effect from the NNRTI group is a skin rash. 1, 3, 5 Approximately 16% of the patients who had taken NVP presented with a mild to moderate maculopapular rash (with or without purities) on the trunk, face, and extremities. These alterations most commonly begin after two weeks of therapy. 5, 19 In the present case the patient did not present with skin or systemic alteration related to NVP.
HAART was suspended indefinitely, and the patient is currently under medical control showing no opportunistic infection or any other complaints. The suspension of the antiretroviral therapy is a form of medical management in cases of adverse effects. In addition, the patient presented a stable immunological profile with a high CD4 cell count (532 cells/mm 3 ) and a decrease in viral load (255 copies/mL).
HAART has significantly improved the prognosis of HIV patients and has proven to control viral replication. 4, 6, 8, 9 Three years and five months after evaluation, were not related to these symptoms. The xerostomia may be related to lamivudine as reported by Scully and Dios. 7 Overall, NVP has a favorable safety profile suggesting it is safe and well-tolerated in both adult and pediatric patients. 1, 3, 7, [14] [15] [16] According to Pollard et al., 16 adverse event data from long-term clinical trials demonstrated a lower incidence of NVP-related adverse events than in short-term trials of NVP therapy. With data from long-term studies supporting continuous treatment being one of the tenets of antiretroviral therapy, NVP would appear to present good tolerability when compared with the safety profiles of other HIV therapies. Orofacial adverse side effects of NVP include erythema multiforme and ulcers. Systemically, NVP has produced elevated liver enzymes, fever, nausea, vomiting, diarrhea, headache, abdominal pain, mialgia, rhinitis, influenza-like symptoms, and erythema multiforme. 1, 3, 7, [14] [15] [16] Recent studies have shown NVP may also lead to an increase in both highdensity lipoprotein and low-density lipoprotein Table 2 . Orofacial adverse effects of specific antiretroviral therapies.* * In accordance to the Scully and Dios. 7 an older population or in smokers. However, this patient was a non-smoker.
HAART has been frequently used in similar cases, but its use has been decreasing due to its adverse effects. The present case suggests a Type II hypersensitivity reaction due to the complement dependent reaction mechanism. This type of reaction may well occur as a reaction to specific medication. 20 
Summary
Although HAART is very important in the treatment of HIV, its side effects are responsible for patients' non-adherence to medications. To our knowledge, this case represents the first report of an oral reaction stemming from NVP usage. Nevertheless, more studies are needed to better understand its inner workings. After suspending HAART, the complete resolution of the signs and symptoms was observed. Therefore, physicians and dentists alike must understand how to identify and prevent these adverse effects in order to further improve HIV patient treatments.
having suspended treatment the patient's CD4 lymphocyte count was never lower than the limit of 200 cells/mm 3 but it was reduced to 343 cells/ mm 3 . In contrast, the patient's viral load increased by approximately ten fold, reaching 2.489 copies/ mL. It is important to emphasize the advantages and disadvantages of switching the patient's medications. The advantages are the possibilities of avoiding or eliminating adverse effects related to specific HAART medications as was found in the present case. The disadvantages are related to the resistance to HIV and the patient's nonadherence to medications. 13 Since the clinical features of the oral adverse effect due to NVP are not well known they must be differentiated from other whitish lesions on the oral mucosa. A differential diagnosis may include pseudomenbranous candidiasis and idiopathic or smoking-related leukoplakia. 19 Pseudomenbranous candidiasis can be differentiated from an oral adverse effect due to NVP as the latter is non-removable. Idiopathic or smoking-related leukoplakia generally occurs in
